Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|October 27, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-11-04-2015
- Volume 11
- Issue 11
Rx-360 Names Mark Paxton as New CEO
Author(s)Pharmaceutical Technology Editors
Rx-360 announced that Mark S. Paxton has been appointed as the new chief executive office of the international pharmaceutical supply chain consortium. This appointment follows the successful growth of Rx-360 since its foundation in 2009 in the aftermath of the adulterated heparin tragedy. Rx-360 has 300 volunteers from more than 100 institutions that are organized in 17 working groups with activities in the US, Europe, China, and India.
Advertisement
Rx-360 announced that Mark S. Paxton has been appointed as the new chief executive office of the international pharmaceutical supply chain consortium. This appointment follows the successful growth of Rx-360 since its foundation in 2009 in the aftermath of the adulterated heparin tragedy. Rx-360 has 300 volunteers from more than 100 institutions that are organized in 17 working groups with activities in the US, Europe, China, and India.
Paxton will lead the consortium and its membership in executing the
Source:
Articles in this issue
almost 11 years ago
New Reagents and Reactions Advance Fluorination Chemistryalmost 11 years ago
CMOs Ride Continuing Strength of Small-Molecule Drug Sectoralmost 11 years ago
Lubrizol Introduces Topical Filmalmost 11 years ago
FDA Extends Compliance Dates for Drug Dispensersalmost 11 years ago
Ashland Presents Scientific Studies for Drug Formulationalmost 11 years ago
Xcelience Opens New Headquartersalmost 11 years ago
IPEC-America Suggests Improvements to FDA’s Inactive Ingredients Databasealmost 11 years ago
Catalent Expands Cold-Chain Capacity at Shanghai Facilityalmost 11 years ago
Croda's French Facility Receives EXCiPACT Certificationalmost 11 years ago
Capsugel Launches enTRinsic Drug Delivery Technology PlatformAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
5